Kunshi Biotechnology
Kunshi Biotechnology is a drug developer with an emphasis on solid tumor cells.
Kunshi Biotechnology is a drug developer with an emphasis on solid tumor cells.
Kunshi Biotechnology has raised $7.0M across 1 round. Its most recent round was a Series A of $7.0M in Nov 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Kunshi Biotechnology is featured in
Similar companies
Weike Bio is a gene therapy drug development company.
Full-Life Technologies is a medical company providing development, production, and commercialization of medicines for cancer therapy.
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
Twinpig Biolab researches and develops anticancer drugs.
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Neok Bio is a biotech startup that focuses on bispecific ADCs in cancer therapy.
BOOST Pharma develops a stem cell therapy for the treatment of osteogenesis imperfecta.
Step Pharma is a biotechnology company.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.